137 related articles for article (PubMed ID: 23231086)
1. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
Tedder RS; Tuke P; Wallis N; Wright M; Nicholson L; Grant PR
J Viral Hepat; 2013 Jan; 20(1):65-71. PubMed ID: 23231086
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.
Pradat P; Maynard M; Buti M; Berthillon P; Picchio G; Tillmann HL; Wiegand J; Voirin N; Manns MP; Esteban JI; Martinot M; Marcellin P; Trepo C
J Med Virol; 2004 Jul; 73(3):392-6. PubMed ID: 15170634
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy.
Maynard M; Pradat P; Berthillon P; Picchio G; Voirin N; Martinot M; Marcellin P; Trepo C
J Viral Hepat; 2003 Jul; 10(4):318-23. PubMed ID: 12823600
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
Vermehren J; Susser S; Berger A; Perner D; Peiffer KH; Allwinn R; Zeuzem S; Sarrazin C
J Clin Virol; 2012 Sep; 55(1):17-22. PubMed ID: 22698697
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.
Buti M; Mendez C; Schaper M; Sauleda S; Valdes A; Rodriguez-Frias F; Jardi R; Esteban R
J Hepatol; 2004 Mar; 40(3):527-32. PubMed ID: 15123370
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.
González V; Padilla E; Diago M; Giménez MD; Solà R; Matas L; Montoliu S; Morillas RM; Pérez C; Planas R
J Viral Hepat; 2005 Sep; 12(5):481-7. PubMed ID: 16108762
[TBL] [Abstract][Full Text] [Related]
9. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
[TBL] [Abstract][Full Text] [Related]
12. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL
J Clin Virol; 2017 Jul; 92():32-38. PubMed ID: 28521211
[TBL] [Abstract][Full Text] [Related]
14. [Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
Higashimoto M; Takahashi M; Jokyu R; Saito H
Rinsho Byori; 2006 Feb; 54(2):111-5. PubMed ID: 16548229
[TBL] [Abstract][Full Text] [Related]
15. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
16. Utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
Wang L; Chen W; Xi W; Feng J; Dang P; Ma Y; Yu Y
J Med Virol; 2017 Jul; 89(7):1235-1240. PubMed ID: 27958657
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.
Terrault NA; Pawlotsky JM; McHutchison J; Anderson F; Krajden M; Gordon S; Zitron I; Perrillo R; Gish R; Holodniy M; Friesenhahn M
J Viral Hepat; 2005 Sep; 12(5):465-72. PubMed ID: 16108760
[TBL] [Abstract][Full Text] [Related]
19. Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads.
Enomoto M; Nishiguchi S; Tamori A; Kohmoto M; Habu D; Sakaguchi H; Takeda T; Kawada N; Seki S; Shiomi S
J Med Virol; 2005 Sep; 77(1):77-82. PubMed ID: 16032731
[TBL] [Abstract][Full Text] [Related]
20. The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.
Kamal SM; Kassim S; El Gohary E; Fouad A; Nabegh L; Hafez T; Bahnasy K; Hassan H; Ghoraba D
Aliment Pharmacol Ther; 2015 Aug; 42(3):307-18. PubMed ID: 26018116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
